TIGIT and neoplasm: Further research is required to fully elucidate if PD-1 or TIGIT blockade hold real potential as new treatment options and using more complex tumour models such as tumour organoids and patient-derived xenograft models to encapsulate the heterogeneous landscape of OAC will be essential.